Literature DB >> 7833125

Hepatitis C virus infection and B-cell lymphomas.

C Ferri, F Caracciolo, L La Civita, M Monti, G Longombardo, F Greco, A L Zignego.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7833125     DOI： 10.1016/0959-8049(94)90066-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  6 in total

Review 1.  Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options.

Authors:  Gabriele Pozzato; Cesare Mazzaro; Luigino Dal Maso; Endri Mauro; Francesca Zorat; Giulia Moratelli; Pietro Bulian; Diego Serraino; Valter Gattei
Journal:  World J Hepatol       Date:  2016-01-18

Review 2.  Hepatitis C virus-related lymphoproliferative disorders: an overview.

Authors:  Anna-Linda Zignego; Carlo Giannini; Clodoveo Ferri
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

Review 3.  New insights into HCV-related rheumatologic disorders: A review.

Authors:  Patrice Cacoub; Cloé Comarmond
Journal:  J Adv Res       Date:  2016-07-25       Impact factor: 10.479

4.  Second primary cancers following non-Hodgkin's lymphoma in Japan: increased risk of hepatocellular carcinoma.

Authors:  H Tanaka; H Tsukuma; H Teshima; W Ajiki; Y Koyama; N Kinoshita; T Masaoka; A Oshima
Journal:  Jpn J Cancer Res       Date:  1997-06

Review 5.  A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy.

Authors:  Cesare Mazzaro; Luca Quartuccio; Luigi Elio Adinolfi; Dario Roccatello; Gabriele Pozzato; Riccardo Nevola; Maurizio Tonizzo; Stefano Gitto; Pietro Andreone; Valter Gattei
Journal:  Viruses       Date:  2021-11-09       Impact factor: 5.048

Review 6.  Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact.

Authors:  Anna Linda Zignego; Carlo Giannini; Laura Gragnani; Alessia Piluso; Elisa Fognani
Journal:  J Transl Med       Date:  2012-08-03       Impact factor: 5.531
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.